Guardant Health, Inc. splits its revenue into 4 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Oncology at $231.3 million, 64% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,279
|
361
|
335
|
302
|
281
|
265
|
232
|
203
|
202
|
| Oncology |
845
+32.2%
share 66.1%
|
231
+25.4%
share 64.1%
|
219
+38.1%
share 65.4%
|
205
+36.1%
share 67.9%
|
190
+30.4%
share 67.5%
|
184
share 69.5%
|
159
share 68.4%
|
151
share 74.0%
|
146
share 72.2%
|
| Screening |
197
+304.7%
share 15.4%
|
68
+180.4%
share 18.7%
|
53
+256.9%
share 15.8%
|
42
+632.6%
share 13.8%
|
35
+752.4%
share 12.5%
|
24
share 9.1%
|
15
share 6.4%
|
6
share 2.8%
|
4
share 2.0%
|
| Biopharma Data |
227
+10.3%
share 17.7%
|
59
+7.7%
share 16.3%
|
61
+8.8%
share 18.2%
|
53
+16.8%
share 17.6%
|
54
+9.1%
share 19.2%
|
55
share 20.6%
|
56
share 24.1%
|
45
share 22.3%
|
50
share 24.5%
|
| Licensing Other |
10
+6.3%
share 0.7%
|
3
+60.2%
share 0.9%
|
2
-19.8%
share 0.6%
|
2
+15.3%
share 0.7%
|
2
-15.0%
share 0.8%
|
2
share 0.7%
|
3
share 1.1%
|
2
share 0.9%
|
3
share 1.3%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- GH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1576280
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.